home / stock / mtnb / mtnb news

MTNB News and Press, Matinas Biopharma Holdings Inc.

Stock Information
Company Name: Matinas Biopharma Holdings Inc.
Stock Symbol: MTNB
Market: NYSE
Website: matinasbiopharma.com
Menu
MTNB MTNB Quote MTNB Short MTNB News MTNB Articles MTNB Message Board
Get MTNB Alerts

News, Short Squeeze, Breakout and More Instantly...
MTNB - Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
MTNB - Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...

MTNB - New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...

MTNB - Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript

2024-05-09 19:47:06 ET Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Conference Call May 09, 2024, 16:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Office...
MTNB - Matinas Biopharma GAAP EPS of -$0.03 in-line, no revenue

2024-05-09 16:30:20 ET More on Matinas Biopharma Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript Matinas BioPharma prices $10 million registered direct offering Seeking Alpha’s Quant Rating on Matinas Biopharma Historical earni...

MTNB - Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company’s strategy to expand its LNC platform into in...

MTNB - Notable earnings after Thursday's close

2024-05-08 17:35:55 ET Major earnings expected after the bell on Thursday include: Unity Software ( U ) Main Street Capital Corporation ( MAIN ) Marathon Digital Holdings ( MARA ) Wheaton Precious Metals Corp. ( WPM ) Blink Charging Co. ( BLNK ) ...
MTNB - Matinas Biopharma Q1 2024 Earnings Preview

2024-05-08 17:35:05 ET More on Matinas Biopharma Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript Matinas BioPharma prices $10 million registered direct offering Read the full article on Seeking Alpha For further details see: Matin...

MTNB - Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James J. ...

MTNB - Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report fi...
Next 10